Funding for this research was provided by:
Canadian Institutes of Health Research (PJT-153424, UD1-170148, SMC-151518)
Fonds de Recherche du Québec - Santé (256141, 34757, 251618, 309815)
J.W. McConnell Memorial Graduate Fellowships
Canada Research Chairs (950-232522)
Université du Québec à Montréal
Article History
Received: 20 March 2022
Revised: 7 September 2022
Accepted: 12 September 2022
First Online: 28 September 2022
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Mr. Woods has no conflicts of interest to report. Dr. Lavoie has served on the advisory board for Schering-Plough, Takeda, AbbVie, Almirall, Janssen, GSK, Astellas, Novartis, Boehringer Ingelheim (BI), and Sojecci Inc. and received sponsorship for investigator-generated research grants from GSK and AbbVie; speaker fees from GSK, Astra-Zeneca, Astellas, Novartis, BI, Takeda, Janssen, AbbVie, Merck, Bayer, Pfizer, and Air Liquide; and support for educational materials from Merck, none of which are related to the current article. Dr. Bacon has received consultancy fees from Merck for the development of behavior change continuing education modules and speaker fees from Novartis and Janssen and has served on advisory boards for Bayer, Sanofi, and Sojecci Inc., none of which are related to the current article.